Halozyme Therapeutics’ (HALO) Buy Rating Reiterated at HC Wainwright

Halozyme Therapeutics (NASDAQ:HALO)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports.

A number of other equities analysts have also weighed in on the company. Piper Sandler increased their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Benchmark reiterated a “buy” rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Finally, Wells Fargo & Company cut their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $62.78.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $59.53 on Thursday. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The firm’s 50 day moving average is $55.20 and its 200-day moving average is $54.74. Halozyme Therapeutics has a 12-month low of $37.73 and a 12-month high of $65.53. The stock has a market capitalization of $7.33 billion, a P/E ratio of 17.36, a P/E/G ratio of 0.42 and a beta of 1.25.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million. Equities research analysts anticipate that Halozyme Therapeutics will post 4.73 EPS for the current fiscal year.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 1,697 shares of the company’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the transaction, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at $10,126,499.68. This represents a 0.97 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the sale, the director now owns 38,611 shares of the company’s stock, valued at approximately $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 31,697 shares of company stock worth $1,754,451. Corporate insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Halozyme Therapeutics in the fourth quarter worth $10,032,000. Heck Capital Advisors LLC acquired a new stake in shares of Halozyme Therapeutics in the fourth quarter worth about $29,000. Armis Advisers LLC bought a new stake in shares of Halozyme Therapeutics during the 4th quarter worth about $295,000. GF Fund Management CO. LTD. acquired a new position in shares of Halozyme Therapeutics during the 4th quarter valued at about $128,000. Finally, Novem Group bought a new position in shares of Halozyme Therapeutics in the 4th quarter valued at approximately $841,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.